Canakinumab in pediatric rheumatic diseases

Bibliography

• Feldmann J, Prieur AM, Quartier P, Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71(1):198-203
   PubMed Web of Science ®Google Scholar
• Hassink SG, Goldsmith DP. Neonatal onset multisystem inflammatory disease. Arthritis Rheum 1983;26(5):668-73
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50(2):607-12
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Lowe P, Felix SD, In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206(5):1029-36
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360(23):2416-25
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Nowak M, Mallah M, De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46(12):3340-8
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355(6):581-92
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Patel DD. Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. Arthritis Rheum 2004;50(2):345-9
   PubMed Web of Science ®Google Scholar
• Neven B, Marvillet I, Terrada C, Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010;62(1):258-67
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13(6):R202
   PubMed Web of Science ®Google Scholar
• Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47-59
   PubMedGoogle Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19(3):424-30
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31(2):390-2
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ilowite NT, Lovell DJ, Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60(9):2794-804
   PubMed Web of Science ®Google Scholar
• Quartier P, Taupin P, Bourdeaut F, Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48(4):1093-101
   PubMed Web of Science ®Google Scholar
• Frosch M, Ahlmann M, Vogl T, The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60(3):883-91
   PubMed Web of Science ®Google Scholar
• Holzinger D, Frosch M, Kastrup A, The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2012;71(6):974-80
   PubMed Web of Science ®Google Scholar
• Frosch M, Vogl T, Seeliger S, Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003;48(9):2622-6
   PubMed Web of Science ®Google Scholar
• Gattorno M, Piccini A, Lasiglie D, The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58(5):1505-15
   PubMed Web of Science ®Google Scholar
• de Jager W, Hoppenreijs EP, Wulffraat NM, Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007;66(5):589-98
   PubMed Web of Science ®Google Scholar
• de Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25(2):203-7
   PubMed Web of Science ®Google Scholar
• Allantaz F, Chaussabel D, Stichweh D, Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007;204(9):2131-44
   PubMed Web of Science ®Google Scholar
• Muller K, Herner EB, Stagg A, Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998;37(5):562-9
   PubMedGoogle Scholar
• Nigrovic PA, Mannion M, Prince FH, Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63(2):545-55
   PubMed Web of Science ®Google Scholar
• Lequerre T, Quartier P, Rosellini D, Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67(3):302-8
   PubMed Web of Science ®Google Scholar
• Swart JF, Barug D, Mohlmann M, Wulffraat NM. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Expert Opin Biol Ther 2010;10(12):1743-52
   PubMed Web of Science ®Google Scholar
• Ilowite N, Porras O, Reiff A, Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28(2):129-37
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70(5):747-54
   PubMed Web of Science ®Google Scholar
• Ogilvie EM, Khan A, Hubank M, Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56(6):1954-65
   PubMed Web of Science ®Google Scholar
• Fall N, Barnes M, Thornton S, Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 2007;56(11):3793-804
   PubMed Web of Science ®Google Scholar
• Barnes MG, Grom AA, Thompson SD, Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arthritis Rheum 2009;60(7):2102-12
   PubMed Web of Science ®Google Scholar
• Hinks A, Barton A, Shephard N, Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. Arthritis Rheum 2009;60(1):258-63
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Bracci-Laudiero L, Alivernini S, Interleukin-1beta and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med 2010;16(11-12):552-7
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348(25):2583-4
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58(8):2443-52
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Evans RR, Saag KG, Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012;64(10):1462-70
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Spalding SJ, Giannini EH, Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012;157(8):533-41
   PubMed Web of Science ®Google Scholar
• Ilowite NT, Sandborg CI, Feldman BM, Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J 2012;10(1):31
   PubMedGoogle Scholar
• Kuemmerle-Deschner JB, Hachulla E, Cartwright R, Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70(12):2095-102
   PubMed Web of Science ®Google Scholar
• Ruperto N, Quartier P, Wulffraat N, A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64(2):557-67
   PubMed Web of Science ®Google Scholar
• Ruperto N, Brunner H, Horneff G, Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1b antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study. Pediatric Rheumatology 2011;9(Suppl 1):O21
   PubMedGoogle Scholar
• Ruperto N, Brunner HI, Quartier P, Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367(25):2396-406
   PubMed Web of Science ®Google Scholar
• Toplak N, Frenkel J, Ozen S, An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis 2012;71(7):1177-82
   PubMed Web of Science ®Google Scholar
• de Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 6th edition. Elsevier; Amsterdam: 2011. p. 236-48
   Google Scholar
• de Benedetti F, Brunner HI, Ruperto N, Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med 2012;367(25):2385-95
   PubMed Web of Science ®Google Scholar
• Dewitt EM, Kimura Y, Beukelman T, Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012;64(7):1001-10
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63(4):465-82
   PubMed Web of Science ®Google Scholar
• Beukelman T, Haynes K, Curtis JR, Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64(4):1263-71
   PubMed Web of Science ®Google Scholar